CHRM5
ENSG00000184984
Target class
GPCR
Chromosome
15
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- CHRM5
- Gene name
- Cholinergic receptor muscarinic 5
- Gene symbol
- CHRM5
- Protein name
- Muscarinic acetylcholine receptor M5
- Gene biotype
- Protein coding
- Gene family
- Cholinergic receptors muscarinic
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 1.73
- Tissue specificity (Gini)
- 0.472
- Tissue specificity (tau)
- 0.84
- KEGG gene identifiers
- hsa:1133
- Protein interaction confidence
- 0.914571
- Protein interaction partners
- 7
- R-HSA-390648
- R-HSA-416476
- End position
- 34067458
- Start position
- 33968497
- Chromosome
- 15
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein. Postsynaptic cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.840332
- Expression inequality (Gini)
- 0.472352
Expression in transcripts per million
- Brain - Hypothalamus
- 1.73
- Brain - Spinal cord (cervical c-1)
- 1.49
- Brain - Substantia nigra
- 1.36
- Testis
- 1.31
- Brain - Cerebellum
- 0.57
Expression in transcripts per million
- Brain - Hypothalamus1.73
- Brain - Spinal cord (cervical c-1)1.49
- Brain - Substantia nigra1.36
- Testis1.31
- Brain - Cerebellum0.57
- Brain - Cerebellar Hemisphere0.52
- Nerve - Tibial0.52
- Spleen0.41
- Brain - Hippocampus0.4
- Liver0.36
- Small Intestine - Terminal Ileum0.31
- Brain - Nucleus accumbens (basal ganglia)0.29
- Fallopian Tube0.28
- Brain - Frontal Cortex (BA9)0.28
- Lung0.28
- Pituitary0.27
- Brain - Cortex0.27
- Cervix - Ectocervix0.26
- Skin - Not Sun Exposed (Suprapubic)0.25
- Skin - Sun Exposed (Lower leg)0.25
- Brain - Amygdala0.25
- Cervix - Endocervix0.24
- Artery - Tibial0.23
- Thyroid0.23
- Artery - Aorta0.23
And 29 more, listed on the interactive page.
- GO:0007197
- GO:0007213
Cellular components
- GO:0005886
- GO:0004435
- GO:0005515
- GO:0016907
increased salivation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased salivation
Biological samples
- nervous system
PubMed 28216264
receptor binding
Studies
- biochemical: NVS_GPCR_hM5, is one of one assay component(s) measured or calculated from the NVS_GPCR_hM5 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (1,466)
- : Vascular Function in Health and Disease
- 0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium Change
- 0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
- 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
- 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24hr Effects of Tiotropium Bromide in Tetraplegia
- 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- 28-day Repeat Dose Study of GSK573719
- 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
- A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
Drugs (50)
- Aceclidine
- Acetylcholine
- Acetylcholine chloride
- Aclatonium
- Aclidinium
- Aclidinium bromide
- Afacifenacin Muscarinic acetylcholine receptor antagonist
- Amiodarone
- Amitriptyline
- Arecoline
- Atropine
- Benztropine
- Bethanechol
- Biperiden
- Brucine
- Carbachol
- Carbamoylcholine
- Darifenacin
- Darotropium Muscarinic acetylcholine receptor antagonist
- Darotropium bromide Muscarinic acetylcholine receptor antagonist